© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Genitourinary Cancers
CheckMate-9ER Shows Efficacy of Nivolumab/Cabozantinib Combo in RCC
September 25, 2020
Bradley McGregor, MD, discusses the CheckMate-9ER trial of nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Investigators Examine Biomarkers of Response to Avelumab in Urothelial Carcinoma
September 20, 2020
Biomarkers of immune activity were linked with overall survival benefit to frontline maintenance avelumab in patients with advanced urothelial cancer, according to data presented at the ESMO Virtual Congress 2020 from an exploratory analysis of the phase 3 JAVELIN Bladder 100 trial.
Sacituzumab Govitecan Sustains Clinical Activity in Patients With Heavily Pretreated mUC
September 20, 2020
Final results from cohort 1 of the phase 3 TROPHY-U-01 trial reported continued significant activity with sacituzumab govitecan-hziy as treatment of patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.
Statistical Analyses Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC
May 31, 2020
Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel over abiraterone acetate or enzalutamide as a standard treatment in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents, according to results presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.
DFS Improvement Falls Short With Anti–PD-L1 in Muscle-Invasive Urothelial Cancer
May 31, 2020
"Irrespective of the PD-L1 status, there were no trends in favor of atezolizumab in both arms."
Combination Therapy With Cabozantinib and Atezolizumab Gains Foothold in Urothelial Carcinoma
May 30, 2020
Patients with urothelial carcinoma who progress after platinum-containing chemotherapy may receive benefit with the combination regimen of cabozantinib and atezolizumab, according to new data from the COSMIC-021 study.
UGN-102 May Serve as Surgical Alternative for Low-Grade NMIBC With Intermediate Risk
May 15, 2020
"These interim data demonstrate that primary chemoablation of low-grade intermediate-risk non–muscle invasive bladder cancer using UGN-102 results in a significant treatment response and encouraging durability."
BCG-Unresponsive NMIBC Responds to Intravesical Adenoviral Gene Therapy
May 15, 2020
"Intravesical nadofaragene firadenovec [recombinant adenovirus interferon alpha achieved a 53.4% CR rate in patients with BCG-unresponsive carcinoma in situ of the bladder."
Combining Immune Checkpoint and Androgen Receptor Inhibitors Yields Positive Responses for mCRPC
April 11, 2020
Pembrolizumab plus enzalutamide in castration- resistant prostate cancer that exhibited enzalutamide resistance led to positive antitumor signals and a favorable safety profile, according to results of the phase II KEYNOTE-199 trial presented at the 2020 Genitourinary Cancers Symposium.
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 07, 2020
The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.